Aphios Corporation products

An enhanced St. John’s Wort botanical product standardized by hyperforin for use as an alternative to prescription antidepressants. Xantol™ is an enhanced St. John’s Wort (SJW) product standardized by hyperforin content [US Patent]. Aphios utilized its patented SuperFluids™ fractionation and manufacturing technologies to develop Xantol™. Aphios is developing Xantol™ for mild to moderate depression, as a natural alternative to prescription antidepressants with adverse side effect profiles.

An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for its soluble and harmless relative, s-APPα. Aphios has successfully developed and patented efficient methods for manufacturing and formulating APH-1104. In 2008, Aphios investigated APH-1104, a less potent analog of APH-1104, as an intravenous formulation for Alzheimer’s disease in an open-label n=1 clinical trial in the Bahamas. Although limited, the preliminary results of this exploratory study were striking and encouraging.